HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer

Similar documents
HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer

IT S ABOUT TIME. IQFISH pharmdx Interpretation Guide THREEHOURSTHIRTYMINUTES. HER2 IQFISH pharmdxtm. TOP2A IQFISH pharmdxtm

Three Hours Thirty Minutes

Dako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis)

Instant Quality FISH. The name says it all.

Instant Quality FISH. The name says it all.

Results you can trust

PRODUCT INFORMATION. New Reagents for Dako CoverStainer. Choose the H&E staining intensity you want.

Breast Cancer Interpretation Guide

Dr. dr. Primariadewi R, SpPA(K)

Molecular Probes Introducing 14 new probes

artus EBV QS-RGQ Kit Performance Characteristics May 2012 Sample & Assay Technologies Analytical sensitivity plasma

HER2 IQFISH pharmdx. Code K th edition

The first and only fully-automated, multiplexed solution for Measles, Mumps, Rubella and Varicella-zoster virus antibody testing

Reviewer's report. Version: 1 Date: 24 May Reviewer: Cathy Moelans. Reviewer's report:

PyroMark Q24 CpG MGMT Handbook

Bio-Rad Laboratories. Hemoglobin Testing. VARIANT II Hemoglobin Testing System For HbA 1c

Bio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c. VARIANT II TURBO Link. Fully-Automated HbA 1c Testing

TGX and TGX Stain-Free FastCast Acrylamide Kits

Priti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract

The following slides were presented at the TIGA Workshop, and are enclosed in the PP show format (*.pps) in order to include all presented details.

Bio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c. VARIANT II TURBO Link System. Fully-Automated HbA 1c Testing

FOOD TESTING RAPID'L.Mono Chromogenic Media. Detect Listeria Species in 24 Hours

Determination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?

Infectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance

Breast cancer: Antibody selection, protocol optimzation controls and EQA

Product Introduction

Chemical compatibility of the Pall QPoint TM Docking Station - Tap Assembly with common surface disinfectants

WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017

T he HER2/neu type 1 tyrosine kinase growth factor

MEDICAL POLICY. Proprietary Information of YourCare Health Plan

Immunohematology. IH-QC Modular System. Select. Combine. Control.

ab Oil Red O (Lipid Stain)

Comparison of Fluorescence and Chromogenic In Situ Hybridization for Detection of HER-2/neu Oncogene in Breast Cancer

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association

ZytoFast CMV Probe (Biotin-labeled)

Interpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use

Assessment Run B HER2 IHC

HercepTest for the Dako Autostainer Code K5207

Journal of Breast Cancer

HercepTest TM Code K5204

Cardiac Assessment Controls

HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer

CANCER. Clinical Validation of Breast Cancer Predictive Markers

Comparison of in situ hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray

BioPlex 2200 Infectious Disease Panels

Improving Food Process Control Using the

Assessment Run B HER2 IHC

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

Welcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016

HER2 ISH (BRISH or FISH)

Prediction of HER2 gene status in Her2 2 þ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations

Image analysis in IHC overview, considerations and applications

HER2/neu Evaluation of Breast Cancer in 2019

ab Luxol Fast Blue Stain (Myelin Stain)

Prediction and Prevention of Type 1 Diabetes

microrna Presented for: Presented by: Date:


COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME

Population- based cancer survival estimates

MENTAL HEALTH CARE. OECD HCQI Expert meeting 17 th of May, Rie Fujisawa

Know for sure! Your Power for Health. PapilloCheck and PapilloCheck high-risk HPV-Genotyping: The Clear Edge in Early Detection of Cervical Cancer.

Supplementary Figure 1

Allied Health: Sustainable Integrated Health Care for all Australians

Infectious Disease Testing. UriSelect 4 Medium. Direct Identification Visibly Reliable

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

FT-Raman Surface Mapping of Remineralized Artificial Dental Caries

FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?

Workflow. Connecting the Pieces For Total Patient Care

Request for Letters of Intent. International Development of H5N1 Influenza Vaccines

31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million

Tobacco control measures in the Dutch National Prevention Agreement and expected tobacco industry responses

Supplementary Online Content

Bio-Rad Laboratories. Cardiac Assessment Controls. Value Assigned for Clinical Laboratory and Point of Care Test Systems

PosterREPRINT INTRODUCTION. 2-D PAGE of Mouse Liver Samples. 2-D PAGE of E.coli Samples. Digestion / Cleanup. EXPERIMENTAL 1-D PAGE of BSA Samples

European Experience and Perspective on Assessing Value for Oncology Products. Michael Drummond Centre for Health Economics, University of York

ACCESS + NAVIGATION + STABILIZATION

Guideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -

Cardiac Assessment Controls A critical element of reliable cardiac testing

CEN/TC 264/WG 39. Ambient air Sampling and analysis of airborne pollen grains and mold spores of allergy networks Volumetric Hirst method

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

Third Party Controls for Your Dade Behring Systems

HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer

Core-Shell Technology for Proteins and Peptides

Global EHS Resource Center

ACCESS + NAVIGATION + STABILIZATION

Immunohistochemical (IHC) HER-2/neu and Fluorescent- In Situ Hybridization (FISH) Gene Amplification of Breast Cancer in Indian Women

BEFLEX CUSTOMER SURVEY 2016

Annexin V-FITC Apoptosis Detection Kit

HRM Series PCB Power Relays

Type 1 Diabetes Australian Research Impact Analysis

WCPT COUNTRY PROFILE December 2017 SWEDEN

ImmunoCAP Systems. Optimized for allergy testing - Precision - Accuracy - Consistency

Urgent Medical Device Correction

Transcription:

P A T H O L O G Y HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer FROM CERTAINTY COMES TRUST For in vitro diagnostic use

HER2 CISH pharmdx Kit HER2 CISH pharmdx Kit is intended for dual-color chromogenic visualization of signals achieved with directly labeled in situ hybridization probes targeting the HER2 gene as well as centromeric region of chromosome 17. The kit is designed to quantitatively determine HER2 gene status in formalin-fixed, paraffin-embedded breast cancer tissue specimens. Red and blue chromogenic signals are generated on the same tissue section for evaluation under bright field microscopy. The CISH procedure can be performed either manually or automated using Dako Autostainer instruments. HER2 CISH pharmdx Kit is indicated as an aid in the assessment of patients for whom Herceptin (trastuzumab) treatment is being considered. Results from the HER2 CISH pharmdx Kit are intended for use as an adjunct to the clinicopathologic information currently used for estimating prognosis in stage II, node-positive breast cancer patients. Quality Control Signals must be clear, well balanced in intensity, distinct and easy to evaluate Normal cells within the sample allow for an internal control of the staining run - Normal cells should have 1-2 clearly visible blue signals and 1-2 clearly visible red signals - Failure to detect signals in normal cells indicates assay failure, and results should be considered invalid - Numeric evaluation of normal cells should give a result corresponding to the expected value for normal diploid cells (1:1) Normal cells within the sample allow for an internal control of the staining run Nuclear morphology must be intact. Numerous ghost-like cells and a general poor nuclear morphology indicate over-digestion of the specimen, resulting in loss or fragmentation of signals Scoring Guide Assessable tissue Score only invasive component of carcinoma Avoid necrotic areas and areas where the nuclear borders are ambiguous Disregard nuclei with weak signal intensity and non-specific staining or high background staining Assessment of HER2 CISH Scan the slide to account for possible heterogeneity Select distinct tumor areas for assessment Begin analysis in upper left quadrant of selected area. Scan from left to right, counting signals in each tumor nucleus

Scan path for signal counting Signal enumeration If a signal appears to have more than one center of origin, and hence has a shape that differs significantly from a circular dot, it should be counted as two In nuclei with high levels of HER2 gene amplification, the HER2 signals may be positioned very close to each other forming a cluster of signals. In these cases the number of HER2 signals cannot be counted, but must be estimated. Special attention must be paid to the blue signals, as clusters of HER2 signals can cover the blue signals making them hard to see Nuclei exhibiting signals of only one color should not be scored Do not score nuclei demonstrating over- or under digestion Adjust microscope focus to locate all signals in individual nuclei In case of doubt, do not include the nuclei in the evaluation Record Counts Count HER2 (red) and CEN-17 (blue) signals in 20 nuclei in representative tumor areas Calculate the HER2/CEN-17 ratio by dividing the total number of HER2 signals by the total number of CEN-17 signals Results at or near the cut-off (1.8 2.2) should be interpreted with caution. In those cases, count an additional 20 nuclei and recalculate the ratio for the 40 nuclei Ratio of HER2/CEN-17 signals HER2 Gene status Result < 2.0 Non-amplified Negative 2.0 Amplified Positive Breast carcinoma stained with HER2 CISH pharmdx Kit Non-amplified result Red/blue ratio < 2 Breast carcinoma stained with HER2 CISH pharmdx Kit Amplified result Red/blue ratio 2 Microscope Recommendations Use a microscope objective of sufficient quality and magnification to allow for optimal scoring of specimens. Adjust light intensity to allow for easy separation of blue and red color. Focus up and down to find all of the signals in the individual nucleus. We recommend that the microscope include 40x and 60x objectives.

Counting Guide Do not count. Nuclei are overlapping, not all areas of nuclei are visible. Do not score nuclei with signals of only one color Count as 3 blue and 21 red signals (cluster estimation) Count as 2 blue and 4 red signal. Signals that appear to have more than one centre of origin should be counted as two signals Do not count over- or under digested nuclei. Missing signals in the centre of nuclei Count as 4 blue and 4 red signals. Signals that appear to have more than one centre of origin, should be counted as two signals Count as 2 blue and 4 red signals Count as 2 blue (1 blue out of focus) and 4 red signals Cluster of red signals hiding blue signals. Go to a higher level of magnification to confirm presence or absence of blue signals. In case of doubt, do not count

2010 Dako PLEASE PHOTOCOPY FOR YOUR USE HER2 CISH pharmdx Kit, Code SK109 Scoring Scheme Date (day 1) of the run: HER2 CISH pharmdx Kit, SK109 Lot: Nucleus No. HER2 score (red) Count signals in 20 nuclei CEN-17 score (blue) Nucleus No. 1 11 2 12 3 13 4 14 5 15 6 16 7 17 8 18 9 19 10 20 Total (1-10) Total (11-20) HER2 score (red) CEN-17 score (blue) For determination of the HER2/CEN-17 ratio, count the number of HER2 signals and the number of CEN-17 signals in the same 20 nuclei and divide the total number of HER2 signals by the total number of CEN-17 signals. If the HER2/CEN-17 ratio is borderline (1.8-2.2), count an additional 20 nuclei and recalculate the ratio for the 40 nuclei. A ratio at or near the cut-off should be interpreted with caution. Total Score (1-20) HER2 CEN-17 HER2/CEN-17 ratio q Ratio < 2: HER2 gene amplification was not observed q Ratio 2: HER2 gene amplification was observed Staining Run Log ID: Specimen ID(s): Date and signature, Technician: Date and signature, Pathologist:

HER2 CISH pharmdx Kit Includes Pre-Treatment Solution (20x concentrated) Pepsin, Ready-to-Use HER2/CEN-17 Probe Mix Stringent Wash Buffer (20x concentrated) Wash Buffer 1 (20x concentrated) Wash Buffer 2 (10x concentrated) Peroxidase Block, Ready-to-use Red Substrate Buffer Blue Substrate Buffer Red Chromogen Blue Chromogen Tissue-Clear -Based Mounting Medium Coverslip Sealant User-Fillable Reagent Bottles CISH Antibody Mix, Ready to use The HER2 CISH pharmdx Kit contains materials necessary to perform 20 consistent, reproducible assays (22 x 22 mm target area) within a maximum of 10 individual staining runs (manual) or 5 individual runs (automated). Related Products Product Name Size Code HER2 FISH pharmdx Kit 20 tests K5331 HercepTest (for manual use) 35 tests K5204 HercepTest for the Dako Autostainer/Autostainer Plus 50 tests K5207 HercepTest for Automated Link Platforms 50 tests SK001 Hybridizer 110V S2450 Hybridizer 220V S2451 Corporate Headquarters Denmark +45 44 85 95 00 www.dako.com Distributors in more than 60 countries Australia +61 2 9502 8700 Austria +43 1 408 43 34 0 Belgium +32 (0) 16 38 72 20 Brazil +55 11 50708300 Canada +1 905 858 8510 China +86 21 6327 1122 Denmark +45 44 85 97 56 Finland +358 9 348 73 950 France +33 1 30 50 00 50 Germany +49 40 69 69 470 Ireland +353 1 479 0568 Italy +39 02 58 078 1 Japan +81 3 5802 7211 The Netherlands +31 20 42 11 100 Norway +47 23 14 05 40 Poland +48 58 661 1879 Spain +34 93 499 05 06 Sweden +46 8 556 20 600 Switzerland +41 41 760 11 66 United Kingdom +44 (0)1 353 66 99 11 United States of America +1 805 566 6655 29023 11AUG10